Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Conference Call February 15, 2024 5:00 PM ET

Company Participants

Claire Mogford – Head, Investor Relations

David Sleath – Chief Executive Officer

Soumen Das – Chief Financial Officer

Conference Call Participants

Maxwell Nimmo – Numis

John Cahill – Stifel

Zachary Gauge – UBS

Robert Jones – BNP Paribas

Frederic Renard – Kepler Cheuvreux

Paul May – Barclays

Pieter Runneboom – Kempen

David Sleath

All right. Good morning, everybody. Welcome to SEGRO’s Full Year 2023 Results Presentation. Thank you all for taking the time to join us here in the room or online. Now the observant of you will have noticed that Soumen is not here in the room with us. You can’t see him yet, but he will be looming large on the screen above us all. And I can tell you that this is the first, but definitely won’t be the last reference today that I make to COVID-19. But Soumen, I hope you all are feeling okay and get well soon.

As usual, I’m going to make a few opening remarks before we go into the body of the presentation, and we will finish with Q&A. Now it was the macro environment that dominated headlines during 2023 as the world adjusted to higher interest rates and try to predict when they were going to settle. And in fact, as we know, it was only in the last few weeks of the year that the folks started to clear and markets gained confidence that we were nearing the end of the rate hike cycle, started turning their focus instead to when we might see the first cuts coming.

The impact of the monetary conditions on the investment market is well documented. But from an occupational market perspective, 2023 was the first time for quite

Source link